Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study
| Autor: | Amitesh Roy, Bogda Koczwara, Kunal Jain, Kelly R. Mead, Stephen Quinn, A. Ayoola, Alison Richards, Sina Vatandoust, David L. Gordon, Chris Karapetis, Ganessan Kichenadasse, Raghu Kumar, Shawgi Sukumaran, Y. Honda-Okubo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
education.field_of_study
medicine.medical_specialty Chemotherapy biology business.industry Influenza vaccine medicine.medical_treatment Population virus diseases Cancer medicine.disease 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Oncology 030220 oncology & carcinogenesis Internal medicine medicine Clinical endpoint biology.protein 030212 general & internal medicine Seroconversion Antibody education business |
| Zdroj: | Supportive Care in Cancer. 28:5411-5417 |
| ISSN: | 1433-7339 0941-4355 |
| Popis: | Influenza virus infection has significant morbidity and mortality in patients with medical co-morbidities who are also immunosuppressed. The efficacy of the seasonal influenza vaccine has not been well studied in patients receiving chemotherapy. We assessed the efficacy of seasonal influenza vaccine in patients with non-haematological malignancy on active treatment (chemotherapy and targeted therapy). A prospective single arm, open label study with 53 patients with non-haematological cancers recruited during the 2011 and 2012 influenza seasons. Participants had one dose of 2011/2012 trivalent vaccine containing strains A/California/7/2009(H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 (Fluvax) prior to or in-between treatment cycles. Haemagglutination inhibition antibody (HIA) titres in serum were measured at baseline 3, 6 and 24 weeks. Primary endpoint: seroconversion rate (SCR) at 3 weeks. Secondary endpoints: Seroconversion was defined as postvaccination ≥ 4-fold increase in HIA titre and sero-protection defined as a HIA ≥ 1:40. The SCR at 3 weeks were 35%, 30% and 22.5% to the H1N1, H3N2 and B/Bris strains, respectively. There were no new cases of late SC at 6 weeks or 24 weeks. The SPR at 3 weeks were 72.5%, 65% and 40%, respectively, to H1N1, H3N2 and B/Bris. The SPR at 24 weeks to H1N1, H3N2 and B/Bris were 40%, 52.5% and 17.5%, respectively. Patients on various solid tumour treatments achieve sero-protection rate congruent with the general population. The sero-protection HIA titres were not sustained at 24 weeks postvaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink